Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96KS0

UPID:
EGLN2_HUMAN

ALTERNATIVE NAMES:
Egl nine homolog 2; Estrogen-induced tag 6; HPH-3; Hypoxia-inducible factor prolyl hydroxylase 1; Prolyl hydroxylase domain-containing protein 1

ALTERNATIVE UPACC:
Q96KS0; A8K5S0; Q8WWY4; Q9BV14

BACKGROUND:
EGLN2, known for its alternative names such as Egl nine homolog 2 and Estrogen-induced tag 6, mediates the hydroxylation of proline residues in target proteins. This enzyme is a key player in the cellular oxygen sensing mechanism, affecting the stability and activity of hypoxia-inducible factors (HIFs) and thereby influencing gene expression under varying oxygen levels.

THERAPEUTIC SIGNIFICANCE:
The exploration of Prolyl hydroxylase EGLN2's function offers promising avenues for therapeutic intervention. By modulating its activity, it is possible to influence the cellular response to hypoxia, which is a critical factor in the progression of various diseases, including cancer and cardiovascular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.